Gilead Sciences (GILD) Land & Improvements (2010 - 2011)
Gilead Sciences' (GILD) quarterly Land & Improvements came in at $149.4 million in Q4 2011, up 8.39% YoY from $137.8 million in Q4 2010, and up 8.39% on a QoQ basis from $137.8 million in Q4 2010.
Gilead Sciences (GILD) Land & Improvements (2010 - 2011) Analysis & Trends
Gilead Sciences (GILD) has 2 years of Land & Improvements data on file, last reported at $149.4 million in Q4 2011.
- Quarterly Land & Improvements rose 8.39% year-over-year to $149.4 million in Q4 2011, while the trailing twelve-month figure through Dec 2011 was $149.4 million (up 8.39% YoY) and the FY2011 annual result came in at $149.4 million, up 8.39% from the prior year.
- Land & Improvements advanced to $149.4 million in Q4 2011, from $137.8 million in the prior quarter.
- In the past five years, Land & Improvements ranged from a high of $149.4 million in Q4 2011 to a low of $137.8 million in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 149.38 Mn |
| Dec 31, 2010 | 137.81 Mn |